The results of combined treatment for stage III lung cancer including the use of intraoperative radiotherapy
Vol. 70 No. 3 (2024), Articles
Vol. 70 No. 3 (2024)

The results of combined treatment for stage III lung cancer including the use of intraoperative radiotherapy

Articles
https://doi.org/10.37469/0507-3758-2013-59-5-606-610
Published 15.12.2013
Research Institute of Oncology of the Siberian Вranch of the Russian Academy of Medical Sciences
Research Institute of Oncology of the Siberian Вranch of the Russian Academy of Medical Sciences; Siberian State Medical University
Research Institute of Oncology of the Siberian Вranch of the Russian Academy of Medical Sciences; Siberian State Medical University
Research Institute of Oncology of the Siberian Вranch of the Russian Academy of Medical Sciences

Abstract

The results of combined treatment including intraoperative radiation therapy (IORT) were assessed in 147 patients with stage III non-small cell lung cancer. Preoperative chemotherapy with paclitaxel/carboplatin followed by surgery with 15 Gy IORT and additional administration of radiosensitization with cisplatin resulted in a significant increase in the 5-year survival rate compared to surgery alone (39.2% and 47.9%, versus 29.2%, p<0.05).
https://doi.org/10.37469/0507-3758-2013-59-5-606-610
PDF (Русский)

References

Завьялов А.А., Мусабаева Л.И., Лисин В.А. и др. Пятнадцатилетний опыт применения интраоперационной лучевой терапии // Сиб. онкол. журн. - 2004. - № 2-3 (10-11). - С. 75-84.

Колбанов К.И. Факторы прогноза при хирургическом лечении больных немелкоклеточным раком легкого (обзор литературы) // Рос. онкол. журн. - 2011. - № 4. - С. 50-55.

Писарева Л.Ф., Одинцова И.Н., Воробьев В.А. и др. Заболеваемость раком легкого населения Томской области // Сиб. онкол. журнал. - 2012. - № 4 (52). - С. 43-47.

Статистика злокачественных новообразований в России и странах СНГ в 2010 г. / Под ред. акад. РАН и РАМН Давыдова М.И. и д.б.н. Аксель Е.М. - М., 2012. - 307 с.

Ahmed S., Birnbaum A.E., Safran H.P. et al. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study // J. Thorac. Oncol. - 2011. - Vol. 6 (8). - P. 1432-1434.

Aristu J., Rebollo J., Martinez-Monge R. et al. Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study // Am. J. Clin. Oncol. - 1997. - Vol. 20. - Р. 276-281.

Betticher D., Schmitz S.F., Totsch M. et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy in prognostic lung of survival in patients with stage III А pN2 non-small cell lung cancer: a multicenter phase II trial // J. Clin. Oncol. - 2003. -Vol. 21. - Р. 1752-1759.

Sakao Y., Okumura S., Mun M. et al. Prognostic heterogeneity in multilevel N2 non-small cell lung cancer patients: importance of lymphadenopathy and occult intrapulmonary metastases // Ann. Thorac. Surg. - 2010. - Vol. 89, N 4. - P. 1060-1063.

Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer // J. Clin. Oncol. - 2012. - Vol. 30. - P. 172-178.

Vandenbroucke E., De Ryck F., Surmont V., van Meerbeeck J.P. What is the role for surgery in patients with stage III non-small cell lung cancer? // Curr. Opin. Pulm. Med. - 2009. - Vol. 15. - P. 295-302.

Westeel V., Milleron B.J., Quoix E.A. et al. Long term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non small cell lung cancer // 2010, J. Clin. Oncol. - 2010. - Vol. 28 (15s): part I, abstract 7003 (ASCO Proceedings).

Zhou G., Zeng T., Wang L., Ma L. Analysis of the Longterm Effect of Intraoperative Radiotherapy (IORT) for Non-Small Cell Lung Carcinoma (NSCLC) // Chin. J. Clin. Oncol. - 2007. - Vol. 4. - 1. - P. 65-70.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...